Controlled clinical study of Harnal on 103 patients with benign prostatic hyperplasia

Objective To observe the treatment effects and safety of Harnal on benign prostatic hyperplasia (BPH). Methods 172 patients with BPH were randomly assigned into Harnal + Finasteride group (n=103) and Finasteride group (n=69). International Prostate Symptom Score (IPSS),and the correlated objective symptoms were recorded before and after treatment. The treatment effects and safety of Harnal on BPH patients were further evaluated. Results After treatment,the IPSS decreased by 9.8±0.6 in the Harnal + Finasteride group,while decreased by 6.7±0.7 in the Finasteride group,which showed significant difference between the two groups (P0.05). There was also significant difference in residual volume of urine,the volume of prostate and Qmax. PSA decreased more in the Harnal + Finasteride group than in the Finasteride group,but without statistical significance (P0.05). Conclusion Harnal could effectively decrease the objective parameters and subjective symptoms. It is safe in the treatment of BPH.